Skip to main content
Premium Trial:

Request an Annual Quote

CyBio, Axxam Collaborate on New Luminescence Screening Assays

NEW YORK, Feb. 9 (GenomeWeb News) - CyBio, a Jena, Germany-based life sciences firm, will use Axxam's microarray technology and automated luminescence screening systems to develop and market new technologies for drug discovery, the companies announced this week.

 

Under the terms of the agreement, Axxam, a drug-discovery firm based in Milan, Italy, will pair its Photina arrays with several CyBio technologies including the CyBi Cellight System, an automated assay platform, and the Lumax flash HT Reader, which enables high-throughput screening, according to the firms.

 

CyBio said that it has already generated new technologies using Axxam's assay technology. Axxam said it is using Photina, a calcium-detecting photoprotein that can be used in high-throughput and ultra-high-throughput screenings, to expand its capabilities as a provider in assays and services in the drug-discovery market.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.